IPI-926 (Saridegib)
-
Technical Data
Description
IPI-926 (Saridegib) is an orally bioavailable inhibitor of the Hedgehog (Hh) pathway with potential antineoplastic activity. Specifically, IPI-926 binds to and inhibits the cell membrane-spanning G-protein coupled receptor SMO, which may result in the suppression of Hh pathway signaling and a decrease in tumor cell proliferation and survival. SMO is activated upon binding of Hh ligand to the cell surface receptor Patched (PTCH); inappropriate activation of Hh signaling and uncontrolled cellular proliferation may be associated with SMO mutations.
Related products
ABT-263 (Navitoclax)
from $50.00
MEK-162 (ARRY-162)
from $60.00
E-7090
from $280.00
E-7080 (Lenvatinib Mesylate)
from $80.00